Stakeholder attitudes and needs regarding cell-free fetal DNA testing by Hill, M et al.
1 
 
 
Stakeholder attitudes and needs regarding cell-free fetal DNA testing 
 
Melissa Hill1,2, Celine Lewis1,2 and Lyn S Chitty1,2 
 
1North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS 
Foundation Trust, London, UK 
2Genetics and Genomic Medicine, UCL Institute of Child Health, London, UK 
 
 
Correspondence to: 
Dr Melissa Hill 
North East Thames Regional Genetics Service 
Level 5, Barclay House  
37 Queen Square  
London WC1N 3BH 
Email: melissa.hill@ucl.ac.uk 
 
  
2 
 
ABSTRACT  
 
Purpose of review 
To explore stakeholder views on cell-free DNA testing and highlight findings important for successful 
implementation and the provision of best practice in counselling.  
Recent findings 
Non-invasive tests based on the analysis of cell-free fetal DNA are now widely available in clinical 
practice and applications are expanding rapidly. It is essential that stakeholder views are considered 
in order to identify and address any ethical and social issues. We provide an overview of stakeholder 
viewpoints and then focus on the key issues of informed decision making, test uptake, service delivery 
and information sources.  
Summary 
Stakeholders are positive about the introduction of cell-free fetal DNA testing into clinical practice. 
They describe both practical and psychological benefits arising from tests that are safe and can 
potentially be performed earlier in pregnancy. Key concerns, which include the potential for these 
tests to have a negative impact on informed decision making and increased societal pressure to have 
testing, can be addressed through careful parent-directed counselling. As applications for these tests 
expand it is increasingly important to develop innovative approaches to facilitate good understanding 
for parents who are offered non-invasive prenatal testing.  
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INTRODUCTION 
 
Following the discovery of cell-free fetal DNA (cffDNA) in maternal plasma [1] non-invasive prenatal 
tests have moved quickly from research to clinical practice. Tests that are currently offered include 
non-invasive prenatal diagnosis (NIPD) for fetal sex determination, fetal rhesus D (RHD) genotyping 
and some single gene disorders, and a highly accurate screening test for aneuploidies referred to as 
non-invasive prenatal testing (NIPT). The rapid speed of translation has been most apparent for NIPT 
where commercial interests have driven the shift from proof-of-concept studies in 2008 through large 
scale validation into clinical practice in 2011 (for review see [2]). Now NIPT is offered in more than 90 
countries [3] and the technology continues to advance with NIPT utilised to detect not only the 
common aneuploidies but also rarer chromosomal changes [4]. 
  
With technology moving at such a fast pace it is important that studies assessing stakeholder views 
and attitudes are conducted to ensure ethical and social issues are identified and addressed so that 
tests can be implemented in a way that meets the needs of service users and providers. Quantitative 
and qualitative approaches have been used to assess the views of future and current service users, 
parents of children with disabilities, the general public and health professionals. The majority of 
studies have focused on NIPT for aneuploidy with researchers gathering views first on the hypothetical 
use of this test [5-15] and, more recently, on experience drawn from use within clinical practice [16-
20]. Researchers have also looked at stakeholder views on NIPD for fetal sex determination [21-24], 
single gene disorders [25-29] and RHD genotyping [30]. The aim of this review was to examine 
stakeholder views on NIPT/D and draw out key findings that inform best practice for counselling 
(summarised in Table 1).  
{Sachs, 2015 #1775}{Skirton, 2014 #1683} 
OVERVIEW OF STAKEHOLDER VIEWPOINTS  
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Stakeholder attitudes to non-invasive tests have generally been very positive. The most commonly 
quoted clinical benefits of NIPT/D are test safety, as the need for invasive testing is either removed or 
reduced, having results available earlier in pregnancy, the relative ease with which the sample for 
testing is taken and, as a result, the potential for improved access to prenatal tests [5, 6, 10, 21, 25-
27]. For NIPT specifically, improvements over traditional screening tests have been highlighted, 
including greater accuracy, increased certainty about the results and the potential to identify cases of 
Down syndrome that might otherwise have been missed [8, 11, 13, 16]. 
 
Stakeholders have also identified a number of psychological benefits including being able to obtain 
reassurance without putting the pregnancy at risk [8, 16] and more meaningful decision making as 
couples can decide about prenatal testing without being influenced by fear of miscarriage or 
uncertainty of results [13]. Many also highlighted the psychological benefits of having results available 
earlier in pregnancy [6, 12, 13, 26]. For couples choosing to terminate the pregnancy, an earlier 
termination was thought to be easier emotionally and more acceptable from an ethical or moral 
viewpoint. For couples deciding to continue with an affected pregnancy, there is more time to come 
to terms with the diagnosis, adjust to the information and seek support.  
 
The most common concerns about NIPT/D focus on the potential for routinisation of testing and the 
resultant negative impact on informed choice. Many stakeholders felt that NIPT/D had the potential 
to be seen as routine or expected as the tests are safe and easy to perform or that NIPT/D may be 
viewed as “just another blood test” as there are so many blood tests during pregnancy [7, 8, 26, 27, 
29]. If NIPT/D is seen as routine parents may not give sufficient thought to the implications of testing 
which could then hinder informed decision making. Another frequently raised concern was that 
parents may feel increased pressure to have testing because NIPT/D is safe [8, 13, 26, 27] as the 
removal of risk to the pregnancy means that there is no “excuse” to decline testing. Feelings of 
pressure could also arise from how the test is described or simply because it is offered by a “trusted” 
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health professional [8]. Stakeholders also discuss how any increase in prenatal testing and 
terminations could lead to a reduction in support structures and resources for children with disabilities 
and a society less tolerant in their attitudes to people who have children with disabilities, all of which 
could further increase feelings of pressure to undertake testing and terminate an affected pregnancy 
[8, 9, 13]. Cost has been highlighted as a concern that will impede equity in access in countries where 
parents have to pay for testing [33]. Other concerns centre on the applications of NIPT/D and the 
potential to ‘misuse’ the technology for sex selection, less serious indications or testing for late onset 
conditions [8, 13, 15].  
 
INFORMED DECISION MAKING 
 
The potential for non-invasive tests to have a negative impact on informed decision making is a key 
concern that is relevant to all applications of non-invasive tests, but is particularly heightened for 
Down syndrome screening with NIPT as numerous studies have shown that uninformed decisions are 
common for women offered traditional screening tests [34, 35]. In addition, women from multiple 
countries and cultures have been shown to emphasise test safety when making decisions about 
prenatal testing [28, 36-38] which suggests choices may not be informed as other attributes of NIPT/D 
have not been considered. There is also evidence that women and health professionals do not see the 
same need for written consent and time for reflection about testing with NIPT as they do with invasive 
testing which suggests that the goal of making an informed decision may not be as clear as it would 
be with an invasive test [39, 40]. Furthermore, as reassurance has been identified as an important 
motivator for accepting NIPT [16, 19], approaches to counselling that omit discussing the implications 
of a positive result, including views on termination or the value of children with disabilities, may mean 
that women defer thinking about these issues, compromising informed decision making and 
potentially leaving them unprepared for a positive result [41]. For this reason, individualised post-test 
counselling and options for ongoing support are critical to help parents who are given an abnormal 
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result to understand the clinical implications and to provide support for decision making about next 
steps [42, 43]. 
 
The first studies to measure informed decision making [19] or assess contributing factors such as 
knowledge [20, 44] when offering NIPT in clinical practice are now emerging. A study from the United 
Kingdom (UK) looking at the introduction of NIPT into the state funded National Health Service (NHS) 
used a formal measure of informed choice and found rates of informed choice were high (89%) in 585 
women offered NIPT. Further assessment is needed to determine whether this finding reflects NIPT 
being offered in a research setting with additional time available for pre-test counselling [19]. In a 
study to assess understanding of NIPT amongst Latina women, Farrell et al [20] found that knowledge 
was lower for women who had declined NIPT. As low knowledge will hinder informed decision making 
this study highlights the need for culturally specific information and support in our increasingly 
multicultural societies [20].   
 
Stakeholders consistently report that concerns about informed decision making could be overcome 
by careful pre-test counselling and a strong focus on the consent procedure [8, 29]. When discussing 
ways of supporting informed decision making, stakeholders suggest the provision of both spoken and 
written information and support the use of formal consent processes to underscore how NIPT/D is 
different from other blood tests in pregnancy [11, 12, 29]. Counselling to promote informed decision 
making should include the benefits and limitations of NIPT/D, with health professionals taking care 
not to focus solely on discussing the safety of NIPT/D, and alternatives that include the option of not 
having a test. Health professionals should also provide balanced information on the conditions being 
tested for, time for reflection and a discourse on the implications of possible test results guided by 
individual values and preferences [45]. Notably, women having NIPT report that the safety and high 
accuracy afforded by NIPT do not eliminate anxiety and uncertainty as these feelings are strongly tied 
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to the decision of what they would do if the baby is affected [46]. Consequently, it is clear that NIPT 
does not simplify the decision-making process and parents need individualised support [46].  
 
UPTAKE OF PRENATAL TESTS  
 
Interest in NIPT/D is high and it is likely that the population opting for prenatal testing will expand as 
women who would not have previously considered prenatal testing due to the risk of miscarriage 
would be willing to have NIPT/D [11, 12, 26].  More couples will take up prenatal testing for 
“information only”, seeking reassurance or to plan and prepare for the birth of an affected child rather 
than using the information to make decisions about termination of pregnancy [10, 12]. This change 
will impact on clinical services as the numbers of couples seeking prenatal testing will increase. It is 
also likely that additional support will be required for those families continuing with a pregnancy that 
is known to be affected.  
 
While it is likely that many parents will opt for NIPT/D, it is critical that health professionals highlight 
the option of not having any testing and discuss alternative prenatal tests. Studies from the United 
States and the Netherlands found that one third of people surveyed reported not wanting any tests 
for Down syndrome [10, 14]. In addition, the possibility of a false positive and the need for a 
confirmatory invasive test can lead women to decline NIPT [46]. There is also evidence that some 
women may prefer to have an invasive test over NIPT/D. Research looking at preferences for prenatal 
tests in multiple countries found that a large proportion of women from countries such as Italy and 
Portugal would choose invasive testing, which can give information about a wider range of 
chromosomal abnormalities, over an NIPT test which only tests for the major trisomies [38]. These 
women wanted the additional information invasive tests provide compared with NIPT as maximising 
information was a priority [38]. Women with very high risk results from traditional screening or other 
8 
 
indications on ultrasound may also prefer to go directly to invasive testing rather than wait for the 
NIPT result first [19, 47]. 
 
EXPANDING USES OF NIPT/D 
 
Generally stakeholders are accepting of non-invasive tests for a wide range of applications, but 
concerns have been raised about where to “draw the line” [13]. Notably, the speed at which new 
screening targets are becoming available with NIPT is rapidly outstripping the development of 
appropriate approaches to counselling and research on stakeholder views.  In addition to T21, T18 and 
T13 several companies now offer testing for sex chromosome aneuploidies, aneuploidies associated 
with high risk for early pregnancy loss (T9, T16, and T22) and microdeletion syndromes [4]. Very few 
studies have examined stakeholder views of these new applications for NIPT [11, 14, 48, 49]. Whilst 
women are generally interested in having tests for sex chromosome aneuploidies and microdeletion 
syndromes [11, 48, 49], some question the usefulness of screening for conditions with variable or 
unknown outcomes [49]. A key finding from this research is that women want to know what is being 
screened for prior to testing as this information is important for weighing up the advantages and 
disadvantages of NIPT relative to other options [11, 49]. Given the expanding range of potential 
conditions, and their rarity, accurate pre-test counselling will become increasingly challenging. 
Professional education as well as research into how best to deliver this information is needed as the 
targets included in NIPT assays will continue to expand and clinicians will be increasingly asked to 
describe complex test options, testing for multiple conditions and the possibility of uncertain and 
incidental ﬁndings.   
  
SERVICE DELIVERY 
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Several studies have addressed how NIPT/D should be delivered. For fetal sex determination and 
single gene disorders where testing is offered to families known to be at high risk, stakeholders prefer 
that NIPD continues to be available through specialist genetic or fetal medicine services to ensure 
appropriate pre- and post-test counselling offered by health professionals with specialist knowledge 
of the condition and experience and training in counselling for prenatal testing [21, 25, 26]. For NIPT 
for aneuploidy strategies for implementation are dependent on existing prenatal care practices and 
may vary between countries. Regardless of where NIPT is offered, pre- and post-test counselling are 
considered essential [12, 50]. There is ongoing debate about whether to offer NIPT as a first line or 
contingent test, particularly in state funded health systems [51]. Many report wanting NIPT offered to 
all women, but accept that contingent testing may be necessary due to the high current costs [44, 47]. 
Results from a survey of health professionals in 28 countries indicates that across and within countries 
there is wide variation in who is offered NIPT, including high risk women only, all pregnant women, 
only women who request it or only women who can pay for it [3]. In addition, the cost of NIPT was 
highly variable and several clinicians suggested that high test costs were limiting implementation and 
precluding equity of access [3]. Several professional bodies have released guidance on NIPT [52-56] 
and research with health professionals offering NIPT in the United States shows that this test is largely 
being implemented according to professional guidelines [17, 18, 57]. However, a cause for concern 
was evidence that NIPT is being offered as a diagnostic test by a significant portion of providers [17, 
57] demonstrating that continuing health professional education and training is essential. 
   
INFORMATION SOURCES 
 
For couples considering NIPT/D information will be derived from multiple sources. In addition to 
information garnered from healthcare professionals at clinical appointments, couples may be 
influenced by what they read in the news media, on websites and in patient information leaflets from 
providers of non-invasive tests. Studies looking at newspaper articles describing non-invasive tests in 
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the UK (79 articles, with 69 on NIPT for DS) [58] and United States (23 articles on NIPT for DS) [59] 
found that the majority of articles were focused on the benefits of NIPT, such as avoiding the risk of 
miscarriage, and did not always address concerns or limitations of the technology. Review of 40 
websites advertising NIPT for aneuploidy found that, whilst some had balanced and accurate 
information, the majority did not provide balanced information that matched recommendations from 
professional guidelines with a key omission being a lack of evidence to support the information 
provided [60]. Only half of the sites provided information on the need for an invasive test to confirm 
a positive NIPT result and only one site mentioned the possibility of inconclusive or failed results [60]. 
As with the news media articles, websites were much more likely to discuss the benefits of NIPT than 
the limitations of these tests. Similarly, evaluation of the quality of information leaflets from five 
commercial providers of NIPT found that none of the pamphlets included all of the content 
recommended by professional bodies [61]. There are, however, a growing number of examples of 
information leaflets based on guidelines from professional bodies that have been developed by expert 
panels of clinicians and patient groups and then either reviewed by focus groups with parents [61] or 
validated with a questionnaire following use in a clinical setting (accessible via www.rapid.nhs.uk).   
  
Health professionals should be aware that when couples attend for pre-test counselling they may have 
incomplete information or unrealistic expectations about NIPT/D derived from the media or internet. 
It is therefore important that in addition to giving information, clinicians should check understanding 
to ensure that misunderstandings arising from other sources have not prevailed.  
 
CONCLUSIONS 
 
Stakeholders are overwhelmingly positive about the introduction of NIPT/D into clinical practice, 
welcoming these new tests that are highly accurate and offer a safer approach to prenatal testing. 
Concerns around the potential for a negative impact on informed decision making and increased 
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societal pressure to have testing can be addressed through careful parent-directed counselling. 
Supporting informed decision making is essential and pre-test counselling should include a discussion 
of the implications of the test result and allow time for reflection. Post-test counselling is also critical 
to ensure parents understand the implications of the results and have personalised support and 
information to aid decision making in pregnancy. This includes making parents aware of the full range 
of options for prenatal testing available and providing information about the benefits and limitations 
of each option, including the option not to have testing. In order to deliver such counselling effectively, 
detailed and comprehensive health professional education is essential. 
 
Continued research considering ethical issues, stakeholder views and implementation strategies is 
essential to ensure NIPT/D is being offered appropriately. The majority of studies to date have been 
conducted in the United States, UK, Hong Kong and the Netherlands. More research is needed from 
other countries as direct comparison between countries has shown clear differences in preferences 
for prenatal tests [38] and how tests are currently being delivered [3]. Research from specific 
population groups such as ethnic or religious groups has thus far been limited and more research is 
needed. In addition, research around stakeholder views of counselling needs has primarily focused on 
pre-test counselling and informed decision making, while these issues are critical it is important not 
to overlook what people feel is most helpful for post-test counselling, particularly in situations where 
parents may not be prepared for an abnormal result. 
 
 
 
 
KEY POINTS 
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 Stakeholders are largely positive about the introduction of cell-free fetal DNA testing into 
clinical practice and highlight both practical and psychological benefits arising from tests that 
are safe, easy to perform and can potentially provide results earlier in pregnancy.   
 
 The most commonly raised concerns about cell-free fetal DNA testing are the potential for a 
negative impact on informed decision making and increased societal pressure to have testing, 
both of which can be addressed through careful parent-directed counselling that includes the 
benefits and limitations of NIPT/D, alternatives, time for reflection and an individualised 
discussion of the implications of possible test results. 
 
 Stakeholders are generally accepting of a wide range of applications for cell-free fetal DNA, 
but as applications expand the counselling process must be adapted to facilitate good 
understanding of the complex test options, testing for multiple conditions and the possibility 
of uncertain and incidental ﬁndings.   
 
 Health professional education will be essential if counselling is to be delivered effectively 
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Table 1: Implications for practice drawn from stakeholder views and published guidance [31,32].  
 
Pre-test 
counselling 
• Provide spoken and written information and emphasise the consent process 
• Information considered important by parents: test accuracy, sensitivity and 
specificity, certainty of the result, risks and alternatives and conditions 
included in the test 
• Use approaches to counselling that alleviate feelings of pressure to test 
• Promote informed decision making by allowing time for reflection and 
through discourse about the impact of results in light of individual values and 
beliefs 
• Provide balanced information on the benefits and limitations of all options 
for prenatal testing, including the option of not having a test 
• NIPT/D should not be presented as a routine test 
• Safety is a key issue for parents, therefore it is important not to “sell” NIPT/D 
because there is no miscarriage risk   
• Make clear what conditions are included in the test, highlight any differences 
in test sensitivity and specificity between test targets and provide neutral and 
up-to-date information about the conditions. 
• For NIPT, explain that this is a screening test, not a diagnostic test and that 
invasive testing is recommended to confirm the result 
• For NIPT, inform women when there is a possibility of incidental findings 
about their own health 
• Check understanding of the information provided in pre-test counselling as 
couples may already have incomplete information or unrealistic expectations 
drawn from the media or provider websites 
• Explain how the results will be conveyed 
• Provide a summary of options for next steps  
Post-test 
counselling 
• Provide the opportunity to discuss results and implications face-to-face 
• Provide support to continue an affected pregnancy if this is what parents 
choose 
• Provide contact details of relevant support groups  
• Be aware that parents may not have faced the possibility of a positive result 
and the implications 
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Service 
delivery 
• Formal regulation of testing and provision of guidance on service delivery 
from professional bodies is essential 
• Ongoing health professional education is important for effective counselling 
 
